Prescribing information




In the RAISE study:

  • REVOLADE significantly improved both SF-36v2 physical and mental summary scores and FACT-Th6 scores compared with baseline (n=135; all p<0.05)2
  • REVOLADE significantly improved 5 out of 8 SF-36v2 domain scores2
Icon of a head with a brain depicting the significant emotional and physical burden of ITP

Bar chart showing the mean changes in health-related QoL during the RAISE study

*Health-related QoL was measured with the acute recall version of the SF-36v2 questionnaire. Fatigue was measured with the vitality domain of the SF-36v2 and supplemented by use of the fatigue subscale of the FACIT-fatigue questionnaire. Physical and mental component summary scores were normalised to the 1998 US Census.1

Abbreviations: ITP, immune thrombocytopenia; QoL, quality of life.


  1. Trotter P, Hill QA. Patient Relat Outcome Meas. 2018;9:369–384.
  2. Cheng G, et al. Lancet. 2011;377:393–402.
  3. Cooper N, et al. Poster presented at the British Haematology Society Annual Meeting, April 16–18, 2018, Liverpool, UK. PO-022.
HCP19-C002g(1) June 2020.

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics:

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310



Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]